Update on the Management of Nonsteroidal Anti-Inflammatory Drug Hypersensitivity

키워드

참고문헌 (100)

1. McGettigan P, "Use of non-steroidal anti-inflammatory drugs that elevate cardiovascular risk : an examination of sales and essential medicines lists in low-, middle-, and high-income countries", PLoS Med, 10, pp.e1001388~ (2013)
2. Pirmohamed M, "Adverse drug reactions as cause of admission to hospital : prospective analysis of 18 820 patients", BMJ, 329, pp.15~19 (2004)
3. Iasella CJ, "Adverse drug reactions : type A(intrinsic)or type B(idiosyncratic)", Clin Liver Dis, 21, pp.73~87 (2017)
4. Lafrance JP, "Selective and non-selective non-steroidal anti-inflammatory drugs and the risk of acute kidney injury", Pharmacoepidemiol Drug Saf, 18, pp.923~931 (2009)
5. Blumenthal KG, "Adverse and hypersensitivity reactions to prescription nonsteroidal anti-Inflammatory agents in a large health care system", J Allergy Clin Immunol Pract, 5, pp.737~743 (2017)
6. Thong BY, "Nonsteroidal anti-inflammatory drug hypersensitivity in the Asia-Pacific", Asia Pac Allergy, 8, pp.e38~ (2018)
7. Lee JH, "An update on the management of aspirin-exacerbated respiratory disease", Expert Rev Respir Med, 12, pp.137~143 (2018)
8. 김윤정, "Cross-reactivity to Acetaminophen and Celecoxib According to the Type of Nonsteroidal Anti-inflammatory Drug Hypersensitivity", Allergy, Asthma & Immunology Research, 6(2), pp.156~162 (2014), 대한천식알레르기학회
9. Stone SF, "Immediate-type hypersensitivity drug reactions", Br J Clin Pharmacol, 78, pp.1~13 (2014)
10. Kowalski ML, "Reply : to PMID 24117484", Allergy, 69, pp.815~816 (2014)
11. Lee TH, "Leukotrienes and aspirin induced asthma", Thorax, 48, pp.1189~1190 (1993)
12. Divekar R, "Diagnostic utility of urinary LTE4 in asthma, allergic rhinitis, chronic rhinosinusitis, nasal polyps, and aspirin sensitivity", J Allergy Clin Immunol Pract, 4, pp.665~670 (2016)
13. Gaber F, "Increased levels of cysteinyl-leukotrienes in saliva, induced sputum, urine and blood from patients with aspirin-intolerant asthma", Thorax, 63, pp.1076~1082 (2008)
14. Liu T, "Prostaglandin E2 deficiency causes a phenotype of aspirin sensitivity that depends on platelets and cysteinyl leukotrienes", Proc Natl Acad Sci U S A, 110, pp.16987~16992 (2013)
15. Steinke JW, "Aspirin activation of eosinophils and mast cells : implications in the pathogenesis of aspirin-exacerbated respiratory disease", J Immunol, 193, pp.41~47 (2014)
16. Buchheit KM, "Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease", J Allergy Clin Immunol, 137, pp.1566~1576 (2016)
17. 최영우, "Which Factors Associated With Activated Eosinophils Contribute to the Pathogenesis of Aspirin-Exacerbated Respiratory Disease?", Allergy, Asthma & Immunology Research, 11(3), pp.320~329 (2019), 대한천식알레르기학회
18. 이종욱, "Complementary Participation of Genetics and Epigenetics in Development of NSAID-exacerbated Respiratory Disease", Allergy, Asthma & Immunology Research, 11(6), pp.779~794 (2019), 대한천식알레르기학회
19. Zuberbier T, "The EAACI", GA2LEN, WAO guideline for the definition, classification, diagnosis and management of urticaria, pp.Allergy, 2018[DOI]
20. Kowalski ML, "Classification of reactions to nonsteroidal antiinflammatory drugs", Immunol Allergy Clin North Am, 33, pp.135~145 (2013)
21. Szczeklik A, "The broken balance in aspirin hypersensitivity", Eur J Pharmacol, 533, pp.145~155 (2006)
22. Doña I, "Eicosanoid mediator profiles in different phenotypes of nonsteroidal anti-inflammatory drug-induced urticaria", Allergy, 74, pp.1135~1144 (2019)
23. Hsieh CW, "A disease marker for aspirininduced chronic urticaria", Int J Mol Sci, 15, pp.12591~12603 (2014)
24. Bae JS, "Significant association of FcepsilonRIalpha promoter polymorphisms with aspirin-intolerant chronic urticaria", J Allergy Clin Immunol, 119, pp.449~456 (2007)
25. Kim SH, "Genetics of hypersensitivity to aspirin and nonsteroidal anti-inflammatory drugs", Immunol Allergy Clin North Am, 33, pp.177~194 (2013)
26. van der Klauw MM, "Drug-associated anaphylaxis : 20 years of reporting in The Netherlands(1974-1994)and review of the literature", Clin Exp Allergy, 26, pp.1355~1363 (1996)
27. Posadas SJ, "Delayed drug hypersensitivity reactions-new concepts", Clin Exp Allergy, 37, pp.989~999 (2007)
28. Mockenhaupt M, "The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal antiinflammatory drugs : a multinational perspective", J Rheumatol, 30, pp.2234~2240 (2003)
29. 이서영, "Phenotypes of Severe Cutaneous Adverse Reactions Caused by Nonsteroidal Anti-inflammatory Drugs", Allergy, Asthma & Immunology Research, 11(2), pp.212~221 (2019), 대한천식알레르기학회
30. Malskat WS, "Tolerance to alternative cyclooxygenase-2 inhibitors in nonsteroidal anti-inflammatory drug hypersensitive patients", Clin Transl Allergy, 3, pp.20~ (2013)
31. Liccardi G, "Safety of celecoxib in patients with adverse skin reactions to acetaminophen(paracetamol)and nimesulide associated or not with common non-steroidal anti-inflammatory drugs", Eur Ann Allergy Clin Immunol, 37, pp.50~53 (2005)
32. Sánchez-Borges M, "Atopy is a risk factor for non-steroidal anti-inflammatory drug sensitivity", Ann Allergy Asthma Immunol, 84, pp.101~106 (2000)
33. Asero R, "Single NSAID hypersensitivity is associated with atopic status", Eur Ann Allergy Clin Immunol, 47, pp.48~53 (2015)
34. Demoly P, "International consensus on drug allergy", Allergy, 69, pp.420~437 (2014)
35. Sánchez-Borges M, "Cofactors and comorbidities in patients with aspirin", NSAID hypersensitivity, 2017, pp.45, 573~578
36. Lee HY, "Identification of phenotypic clusters of nonsteroidal anti-inflammatory drugs exacerbated respiratory disease", Allergy, 72, pp.616~626 (2017)
37. Blanca-Lopez N, "Value of the clinical history in the diagnosis of urticaria", angioedema induced by NSAIDs with cross-intolerance, 2013, pp.43, 85~91
38. Sánchez-Borges M, "Mite-induced inflammation: more than allergy", Allergy Rhinol(Providence), 3, pp.e25~e29 (2012)
39. Marek L. Kowalski, "Seven Steps to the Diagnosis of NSAIDs Hypersensitivity: How to Apply a New Classification in Real Practice?", Allergy, Asthma & Immunology Research, 7(4), pp.312~320 (2015), 대한천식알레르기학회
40. Hoetzenecker W, "Adverse cutaneous drug eruptions : current understanding", Semin Immunopathol, 38, pp.75~86 (2016)
41. Himly M, "IgE-mediated immediate-type hypersensitivity to the pyrazolone drug propyphenazone", J Allergy Clin Immunol, 111, pp.882~888 (2003)
42. Brockow K, "Skin test concentrations for systemically administered drugs--an ENDA", EAACI Drug Allergy Interest Group position paper, 2013, pp.68, 702~712
43. 강민규, "Analysis of Individual Case Safety Reports of Severe Cutaneous Adverse Reactions in Korea", Yonsei Medical Journal, 60(2), pp.208~215 (2019), 연세대학교의과대학[DOI]
44. Kowalski ML, "Hypersensitivity to nonsteroidal anti-inflammatory drugs(NSAIDs)-classification, diagnosis and management : review of the EAACI", ENDA and GA2LEN, Allergy, pp.2011, 66[DOI]
45. DeGregorio GA, "A 1-Day, 90-minute aspirin challenge and desensitization protocol in aspirin-exacerbated respiratory disease", J Allergy Clin Immunol Pract, 7, pp.1174~1180 (2019)
46. Kowalski ML, "Diagnosis and management of NSAID-Exacerbated Respiratory Disease(N-ERD)-a EAACI position paper", Allergy, 74, pp.28~39 (2019)
47. Kowalski ML, "Approaches to the diagnosis and management of patients with a history of nonsteroidal anti-inflammatory drug-related urticaria and angioedema", J Allergy Clin Immunol, 136, pp.245~251 (2015)
48. Zisa G, "Provocation tests with the offending nonsteroidal anti-inflammatory drugs in patients with urticaria", angioedema reactions, 2012, pp.33, 421~426
49. Kowalski ML, "Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs", Allergy, 68, pp.1219~1232 (2013)
50. Aberer W, "Drug provocation testing in the diagnosis of drug hypersensitivity reactions : general considerations", Allergy, 58, pp.854~863 (2003)
51. Sanz ML, "Allergen-induced basophil activation : CD63 cell expression detected by flow cytometry in patients allergic to Dermatophagoides pteronyssinus and Lolium perenne", Clin Exp Allergy, 31, pp.1007~1013 (2001)
52. Gamboa P, "The flow-cytometric determination of basophil activation induced by aspirin and other non-steroidal anti-inflammatory drugs(NSAIDs)is useful for in vitro diagnosis of the NSAID hypersensitivity syndrome", Clin Exp Allergy, 34, pp.1448~1457 (2004)
53. Hemmings O, "Basophil activation test : old and new applications in allergy", Curr Allergy Asthma Rep, 18, pp.77~ (2018)
54. Hagan JB, "Urinary leukotriene E4 to determine aspirin intolerance in asthma : a systematic review and meta-analysis", J Allergy Clin Immunol Pract, 5, pp.990~997 (2017)
55. Choi Y, "Surfactant protein D alleviates eosinophil-mediated airway inflammation and remodeling in patients with aspirin-exacerbated respiratory disease", Allergy, 74, pp.78~88 (2019)
56. Trinh HKT, "Epithelial folliculin enhances airway inflammation in aspirin-exacerbated respiratory disease", Clin Exp Allergy, 48, pp.1464~1473 (2018)
57. Aleksandra Wardzyńska, "Periostin in Exhaled Breath Condensate and in Serum of Asthmatic Patients: Relationship to Upper and Lower Airway Disease", Allergy, Asthma & Immunology Research, 9(2), pp.126~132 (2017), 대한천식알레르기학회
58. Pichler WJ, "The lymphocyte transformation test in the diagnosis of drug hypersensitivity", Allergy, 59, pp.809~820 (2004)
59. Ioana Agache, "Asthma Biomarkers: Do They Bring Precision Medicine Closer to the Clinic?", Allergy, Asthma & Immunology Research, 9(6), pp.466~476 (2017), 대한천식알레르기학회
60. Wöhrl S, "NSAID hypersensitivity-recommendations for diagnostic work up and patient management", Allergo J Int, 27, pp.114~121 (2018)
61. Reddel HK, "GINA 2019 : a fundamental change in asthma management : treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents", Eur Respir J, 53, pp.1901046~ (2019)
62. Marcello C, "Asthma phenotypes : the intriguing selective intervention with Montelukast", Asthma Res Pract, 2, pp.11~ (2016)
63. Ta V, "Survey-defined patient experiences with aspirinexacerbated respiratory disease", J Allergy Clin Immunol Pract, 3, pp.711~718 (2015)
64. Mastalerz L, "Clinical and genetic features underlying the response of patients with bronchial asthma to treatment with a leukotriene receptor antagonist", Eur J Clin Invest, 32, pp.949~955 (2002)
65. Hanania NA, "Omalizumab in severe allergic asthma inadequately controlled with standard therapy : a randomized trial", Ann Intern Med, 154, pp.573~582 (2011)
66. Bardelas J, "A 26-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the effect of omalizumab on asthma control in patients with persistent allergic asthma", J Asthma, 49, pp.144~152 (2012)
67. Hayashi H, "Omalizumab reduces cysteinyl leukotriene and 9α, 11β-prostaglandin F2 overproduction in aspirin-exacerbated respiratory disease", J Allergy Clin Immunol, 137, pp.1585~1587 (2016)
68. Jean T, "Effect of omalizumab on outcomes in patients with aspirin-exacerbated respiratory disease", Allergy Asthma Proc, 40, pp.316~320 (2019)
69. 이지호, "Therapeutic Effect of Omalizumab in Severe Asthma: A Real-World Study in Korea", Allergy, Asthma & Immunology Research, 10(2), pp.121~130 (2018), 대한천식알레르기학회
70. Porcaro F, "Omalizumab in patient with aspirin exacerbated respiratory disease and chronic idiopathic urticaria", Pediatr Pulmonol, 52, pp.E26~E28 (2017)
71. Guillén D, "Aspirin desensitization achieved after omalizumab treatment in a patient with aspirin-exacerbated urticaria and respiratory disease", J Investig Allergol Clin Immunol, 25, pp.133~135 (2015)
72. Yorgancıogˇlu A, "Long-term omalizumab treatment : a multicenter, real-life, 5-year trial", Int Arch Allergy Immunol, 176, pp.225~233 (2018)
73. Varricchi G, "Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders : evidence and unmet needs", Curr Opin Allergy Clin Immunol, 16, pp.186~200 (2016)
74. Emma R, "Mepolizumab in the management of severe eosinophilic asthma in adults : current evidence and practical experience", Ther Adv Respir Dis, 12, pp.1753466618808490~ (2018)
75. Tuttle KL, "A retrospective analysis of mepolizumab in subjects with aspirin-exacerbated respiratory disease", J Allergy Clin Immunol Pract, 6, pp.1045~1047 (2018)
76. Mark Liddament, "Higher Binding Affinity and In Vitro Potency of Reslizumab for Interleukin-5 Compared With Mepolizumab", Allergy, Asthma & Immunology Research, 11(2), pp.291~298 (2019), 대한천식알레르기학회
77. Laidlaw TM, "Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD", J Allergy Clin Immunol Pract, 7, pp.2462~2465 (2019)
78. Gauvreau GM, "Effects of an anti-TSLP antibody on allergen-induced asthmatic responses", N Engl J Med, 370, pp.2102~2110 (2014)
79. Fokkens WJ, "EPOS 2012 : European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists", Rhinology, 50, pp.1~12 (2012)
80. Howard BE, "Oral steroid therapy in chronic rhinosinusitis with and without nasal polyposis", Curr Allergy Asthma Rep, 13, pp.236~243 (2013)
81. Hamilos DL, "Chronic rhinosinusitis : epidemiology and medical management", J Allergy Clin Immunol, 128, pp.693~707 (2011)
82. Mendelsohn D, "Revision rates after endoscopic sinus surgery : a recurrence analysis", Ann Otol Rhinol Laryngol, 120, pp.162~166 (2011)
83. Stryjewska-Makuch G, "The effect of antileukotrienes on the results of postoperative treatment of paranasal sinuses in patients with non-steroidal anti-inflammatory drug-exacerbated respiratory disease", Int Arch Allergy Immunol, 179, pp.281~289 (2019)
84. 김동규, "Does Inflammatory Endotype Change in Patients With Chronic Rhinosinusitis?", Allergy, Asthma & Immunology Research, 11(2), pp.153~155 (2019), 대한천식알레르기학회
85. Naidoo Y, "Long-term outcomes for the endoscopic modified Lothrop", Draf III procedure : a 10-year review, 2014, pp.124, 43~49
86. Fandiño M, "The use of postoperative topical corticosteroids in chronic rhinosinusitis with nasal polyps : a systematic review and meta-analysis", Am J Rhinol Allergy, 27, pp.e146~e157 (2013)
87. Van Gerven L, "Lack of long-term add-on effect by montelukast in postoperative chronic rhinosinusitis patients with nasal polyps", Laryngoscope, 128, pp.1743~1751 (2018)
88. Chandra RK, "Impact of omalizumab therapy on medication requirements for chronic rhinosinusitis", Int Forum Allergy Rhinol, 6, pp.472~477 (2016)
89. Gevaert P, "Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma", J Allergy Clin Immunol, 131, pp.110~116 (2013)
90. Rivero A, "Anti-IgE and anti-IL5 biologic therapy in the treatment of nasal polyposis : a systematic review and meta-analysis", Ann Otol Rhinol Laryngol, 126, pp.739~747 (2017)
91. Bachert C, "Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis : a randomized clinical trial", JAMA, 315, pp.469~479 (2016)
92. Hill J, "Mechanisms of benefit with aspirin therapy in aspirin-exacerbated respiratory disease", Immunol Allergy Clin North Am, 36, pp.735~747 (2016)
93. Perez-G M, "Aspirin and salicylates inhibit the IL-4-and IL-13-induced activation of STAT6", J Immunol, 168, pp.1428~1434 (2002)
94. 공수강, "Aspirin induces IL-4 production: augmented IL-4 production in aspirin-exacerbated respiratory disease", Experimental and Molecular Medicine, 48, pp.1~10 (2016), 생화학분자생물학회
95. White AA, "Aspirin desensitization : faster protocols for busy patients", J Allergy Clin Immunol Pract, 7, pp.1181~1183 (2019)
96. Berges-Gimeno MP, "Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease", J Allergy Clin Immunol, 111, pp.180~186 (2003)
97. Walters KM, "Long-term clinical outcomes of aspirin desensitization with continuous daily aspirin therapy in aspirin-exacerbated respiratory disease", Am J Rhinol Allergy, 32, pp.280~286 (2018)
98. Maurer M, "Positive impact of omalizumab on angioedema and quality of life in patients with refractory chronic idiopathic", spontaneous urticaria : analyses according to the presence or absence of angioedema, 2017, pp.31, 1056~1063
99. Ring J, "Guideline for acute therapy and management of anaphylaxis : S2 Guideline of the German Society for Allergology and Clinical Immunology(DGAKI), the Association of German Allergologists(AeDA), the Society of Pediatric Allergy and Environmental Medicine(GPA), the German Academy of Allergology and Environmental Medicine(DAAU), the German Professional Association of Pediatricians(BVKJ), the Austrian Society for Allergology and Immunology(ÖGAI), the Swiss Society for Allergy and Immunology(SGAI), the German Society of Anaesthesiology and Intensive Care Medicine(DGAI), the German Society of Pharmacology(DGP), the German Society for Psychosomatic Medicine(DGPM), the German Working Group of Anaphylaxis Training and Education(AGATE)and the patient organization German Allergy and Asthma Association(DAAB)", Allergo J Int, 23, pp.96~112 (2014)
100. Scherer K, "Desensitization in delayed drug hypersensitivity reactions--an EAACI position paper of the Drug Allergy Interest Group", Allergy, 68, pp.844~852 (2013)

관련 논문AI추천